Xiao-e Yan

Taizhou, 225326, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Discovery of highly selective and potent HPK1 inhibitors for cancer immunotherapy.

Discovery of highly selective and potent HPK1 inhibitors for cancer immunotherapy.

Journal: European journal of medicinal chemistry
Published: September 28, 2025

Discovery of Potent and Selective Pyrrolo[2,3-d]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations.

Discovery of Potent and Selective Pyrrolo[2,3-d]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations.

Journal: Journal of medicinal chemistry
Published: September 09, 2025

Structural Basis of AZD9291 Selectivity for EGFR T790M.

Structural Basis of AZD9291 Selectivity for EGFR T790M.

Journal: Journal of medicinal chemistry
Published: July 17, 2020

Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.

Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.

Journal: European journal of medicinal chemistry
Published: September 18, 2017

Structural insights into drug development strategy targeting EGFR T790M/C797S.

Structural insights into drug development strategy targeting EGFR T790M/C797S.

Journal: Oncotarget
Published: July 12, 2017

Structural pharmacological studies on EGFR T790M/C797S.

Structural pharmacological studies on EGFR T790M/C797S.

Journal: Biochemical and biophysical research communications
Published: April 20, 2017

Structural basis of mutant-selectivity and drug-resistance related to CO-1686.

Structural basis of mutant-selectivity and drug-resistance related to CO-1686.

Journal: Oncotarget
Published: March 31, 2017

Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.

Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.

Journal: Journal of medicinal chemistry
Published: March 11, 2017

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.

Journal: Oncotarget
Published: December 09, 2016

A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.

A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.

Journal: European journal of medicinal chemistry
Published: September 30, 2016

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.

Journal: Oncotarget
Published: June 08, 2016

Structural and biochemical studies of the PDGFRA kinase domain.

Structural and biochemical studies of the PDGFRA kinase domain.

Journal: Biochemical and biophysical research communications
Published: May 24, 2016
Showing 1-12 of 13

Last Updated: 09/26/2026